Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M85.5Revenue (TTM) $M--Net Margin (%)--Altman Z-Score2.5
Enterprise Value $M22.7EPS (TTM) $-0.3Operating Margin %--Piotroski F-Score3
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yY
Price/Book1.410-y EBITDA Growth Rate %--Quick Ratio9.9Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-28.3Current Ratio9.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-34.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-37.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M95.6ROIC % (ttm)-71.2Gross Margin Increase y-yN

Gurus Latest Trades with BLRX

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

BLRX is held by these investors:



BLRX: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about BLRX:

    News about blrx:

    Articles On GuruFocus.com
    BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares Apr 05 2017 
    BioLineRx Announces Underwritten Public Offering of its American Depositary Shares Mar 31 2017 
    BioLineRx Prices $25 Million Underwritten Public Offering Mar 31 2017 
    Analysts Positive on BioLineRx Ltd. Following Ph2 Testing Expansion for AML May 05 2015 
    Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 

    More From Other Websites
    BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares Apr 05 2017
    Today's Research Reports on Biotech Stocks to Watch: Bioline RX and Cara Therapeutics Apr 03 2017
    BioLineRx Prices $25 Million Underwritten Public Offering Mar 31 2017
    BioLineRx Announces Underwritten Public Offering of its American Depositary Shares Mar 30 2017
    BioLineRx's AGI-134 to be Presented at AACR 2017 Mar 27 2017
    BioLineRx Reports Year End 2016 Financial Results Mar 23 2017
    BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-Oncology... Mar 23 2017
    BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization... Mar 20 2017
    BioLineRx to Report Annual 2016 Results on March 23, 2017 Mar 16 2017
    Two Biotech Catalysts To Watch Right Now: Bioline RX Ltd (BLRX) And AMAG Pharmaceuticals, Inc.... Mar 14 2017
    BioLineRx to Present at 2017 BIO CEO & Investor Conference in New York on February 14 Feb 07 2017
    BioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda Jan 19 2017
    BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of... Jan 17 2017
    BioLineRx to Present at Biotech Showcase 2017 Conference in San Francisco Jan 04 2017
    BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology... Dec 05 2016
    BioLineRx Reports Third Quarter 2016 Financial Results Nov 22 2016
    BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic... Nov 21 2016
    BioLineRx to Report Third Quarter Results on November 22, 2016 Nov 15 2016
    Penny Ante: Ante Up For Bioline RX Ltd (BLRX) Stock Nov 09 2016
    BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data... Nov 03 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)